Literature DB >> 20482514

Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment.

Henning Krampe1, Hannelore Ehrenreich.   

Abstract

Supervised intake of the alcohol deterrent (AD) disulfiram has proven to be an effective adjunct to biopsychosocial alcoholism therapy for more than 60 years. This article summarizes disulfiram literature between 1937 and 2000 and reviews 13 clinical trials of disulfiram in alcoholism treatment from the years 2000 to 2008. After giving an update of general safety issues and recent case reports concerning safety problems with disulfiram, we focus on the introduction of psychotherapeutic application of supervised disulfiram. The results of our review show: (1) Disulfiram proved to be an effective therapeutic tool in all clinical studies published from 2000 to 2008. (2) Comparisons with other pharmacological agents - naltrexone, acamprosate, topiramate and gamma-hydroxybutyrate - indicate that disulfiram was equal in two trials but superior in the majority of trials. (3) Therapy programs that make use of the psychological effects of supervised disulfiram have - independently of the dose - better results than programs that neglect psychological effects. As a consequence, we suggest that supervised low-dose disulfiram (not more than 100mg/d), will show highest success when it is carefully integrated into psychotherapeutic alcoholism therapy. The major program of psychotherapy with disulfiram comprises the steps "Initial psychoeducation about the effect of disulfiram and its therapeutic implications", "Advanced psychoeducation", and "Disulfiram as coping skill and extension of repertoire of coping skills". As psychological mechanisms of supervised disulfiram we suggest: (1) deterrence; (2) (auto)suggestion; (3) therapeutic ritual around (4) a frequently renewed active decision process; (5) continuous reinforcement of a sober lifestyle and development of new coping skills.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482514     DOI: 10.2174/138161210791516431

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  21 in total

Review 1.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

2.  [Pharmacological prophylactic treatment for relapse of alcohol dependence : Results of current meta-analyses].

Authors:  J Mutschler; M Soyka
Journal:  Nervenarzt       Date:  2017-03       Impact factor: 1.214

Review 3.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

Review 4.  New steps for treating alcohol use disorder.

Authors:  Erin J Campbell; Andrew J Lawrence; Christina J Perry
Journal:  Psychopharmacology (Berl)       Date:  2018-03-25       Impact factor: 4.530

5.  [Disulfiram in outpatient treatment of alcohol dependency].

Authors:  K Hochsattel; P Brieger
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

Review 6.  Alcohol Dependence and Harmful Use of Alcohol.

Authors:  Anil Batra; Christian A Müller; Karl Mann; Andreas Heinz
Journal:  Dtsch Arztebl Int       Date:  2016-04-29       Impact factor: 5.594

7.  Adoption of medications in substance abuse treatment: priorities and strategies of single state authorities.

Authors:  Traci Rieckmann; Anne E Kovas; Beth A Rutkowski
Journal:  J Psychoactive Drugs       Date:  2010-09

Review 8.  Pharmacological approaches to reducing craving in patients with alcohol use disorders.

Authors:  Carolina L Haass-Koffler; Lorenzo Leggio; George A Kenna
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

9.  Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

Authors:  Falk W Lohoff
Journal:  Pharmacogenomics       Date:  2020-08-18       Impact factor: 2.533

10.  [Guideline-oriented treatment of alcohol-related disorders].

Authors:  K Mann; E Hoch; A Batra; U Bonnet; A Günthner; G Reymann; M Soyka; N Wodarz; M Schäfer
Journal:  Nervenarzt       Date:  2016-01       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.